Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript
Hi, everyone. I'm Gary Nachman, a senior biopharma analyst at BMO, and we're really excited to have Ionis management participating with us in BMO's Growth and ESG Conference. We have Eugene Schneider, Head of Clinical Development; and Roslyn Patterson, VP of Marketing and Communications.
Ionis has a great platform in RNA-targeted antisense technology with a very robust portfolio across cardiovascular disease and neurology. And the company recently announced a deal with Metagenomi, expanding its capabilities into gene editing. So a lot of exciting programs in the pipeline that we'll be able to cover, and it's great to have you guys here to discuss that with us. So thank you for being here.
Thank you, Gary, for having us.
Questions & Answers
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
